-
1
-
-
4043179907
-
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
-
Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 2580-2589
-
-
Looney, R.J.1
Anolik, J.H.2
Campbell, D.3
-
2
-
-
0033883903
-
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
-
Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
-
(2000)
Arthritis Rheum
, vol.43
, pp. 1790-1800
-
-
Llorente, L.1
Richaud-Patin, Y.2
Garcia-Padilla, C.3
-
3
-
-
0032728801
-
A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response
-
Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-12.
-
(1999)
Lupus
, vol.8
, pp. 705-712
-
-
Levy, Y.1
Sherer, Y.2
Ahmed, A.3
-
4
-
-
2942700114
-
Autologous stem cell transplantation for systemic lupus erythematosus
-
Jayne D, Passweg J, Marmont A et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-76.
-
(2004)
Lupus
, vol.13
, pp. 168-176
-
-
Jayne, D.1
Passweg, J.2
Marmont, A.3
-
5
-
-
0032986483
-
Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
-
Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J Am Soc Nephrol 1999;10:833-9.
-
(1999)
J Am Soc Nephrol
, vol.10
, pp. 833-839
-
-
Dooley, M.A.1
Cosio, F.G.2
Nachman, P.H.3
-
6
-
-
1642501086
-
The NIH pulse cyclophosphamide regime: The end of an era?
-
Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: The end of an era? Lupus 2004;13:1-3.
-
(2004)
Lupus
, vol.13
, pp. 1-3
-
-
Karim, Y.1
D'Cruz, D.P.2
-
7
-
-
0033979772
-
The evolving role of mycophenolate mofetil in renal transplantation
-
Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. Q J Med 2000;93:15-20.
-
(2000)
Q J Med
, vol.93
, pp. 15-20
-
-
Warrens, A.N.1
-
8
-
-
33144475027
-
Mycophenolate mofetil treatment of myasthenia gravis
-
Cahoon WD Jr, Kockler DR. Mycophenolate mofetil treatment of myasthenia gravis. Ann Pharmacother 2006;40:295-8.
-
(2006)
Ann Pharmacother
, vol.40
, pp. 295-298
-
-
Cahoon Jr, W.D.1
Kockler, D.R.2
-
9
-
-
0037825768
-
Mycophenolate mofetil (CellCept) for psoriasis: A two-center, prospective, open-label clinical trial
-
Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate mofetil (CellCept) for psoriasis: A two-center, prospective, open-label clinical trial. J Cutan Med Surg 2003;7:193-7.
-
(2003)
J Cutan Med Surg
, vol.7
, pp. 193-197
-
-
Zhou, Y.1
Rosenthal, D.2
Dutz, J.3
Ho, V.4
-
10
-
-
0034045586
-
Mycophenolate mofetil and its mechanisms of action
-
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
-
(2000)
Immunopharmacology
, vol.47
, pp. 85-118
-
-
Allison, A.C.1
Eugui, E.M.2
-
11
-
-
0035051925
-
Treatment of systemic lupus erythematosus with mycophenolate mofetil
-
Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10:203-8.
-
(2001)
Lupus
, vol.10
, pp. 203-208
-
-
Adu, D.1
Cross, J.2
Jayne, D.R.3
-
12
-
-
0036673864
-
Immunosuppressive therapy in lupus nephritis: The Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
-
Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: The Euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46: 2121-31.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2121-2131
-
-
Houssiau, F.A.1
Vasconcelos, C.2
D'Cruz, D.3
-
13
-
-
28144433147
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
-
Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
-
(2005)
N Engl J Med
, vol.353
, pp. 2219-2228
-
-
Ginzler, E.M.1
Dooley, M.A.2
Aranow, C.3
-
14
-
-
63249110405
-
Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by racial group (abstract)
-
Ginzler EM, Appel GB, Dooley MA et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by racial group (abstract). Rheumatology 2007;56:4308.
-
(2007)
Rheumatology
, vol.56
, pp. 4308
-
-
Ginzler, E.M.1
Appel, G.B.2
Dooley, M.A.3
-
15
-
-
20444466207
-
Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
-
Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16: 1076-84.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 1076-1084
-
-
Chan, T.M.1
Tse, K.C.2
Tang, C.S.3
Mok, M.Y.4
Li, F.K.5
-
16
-
-
1442355581
-
Sequential therapies for proliferative lupus nephritis
-
Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
-
(2004)
N Engl J Med
, vol.350
, pp. 971-980
-
-
Contreras, G.1
Pardo, V.2
Leclercq, B.3
-
17
-
-
33745243801
-
Anti-inflammatory and immuno-suppressive drugs and reproduction
-
Østensen M, Khamashta M, Lockshin M et al. Anti-inflammatory and immuno-suppressive drugs and reproduction. Arthritis Res Ther 2006;8:209.
-
(2006)
Arthritis Res Ther
, vol.8
, pp. 209
-
-
Østensen, M.1
Khamashta, M.2
Lockshin, M.3
-
18
-
-
2542469031
-
Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations
-
Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 2004;103:1091-4.
-
(2004)
Obstet Gynecol
, vol.103
, pp. 1091-1094
-
-
Le Ray, C.1
Coulomb, A.2
Elefant, E.3
Frydman, R.4
Audibert, F.5
-
19
-
-
20444494317
-
Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients
-
Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients. J Rheumatol 2005;32: 1047-52.
-
(2005)
J Rheumatol
, vol.32
, pp. 1047-1052
-
-
Pisoni, C.N.1
Sanchez, F.J.2
Karim, Y.3
-
20
-
-
0041464661
-
Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil
-
Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil. Lupus 2003; 12:630-2.
-
(2003)
Lupus
, vol.12
, pp. 630-632
-
-
Vasoo, S.1
Thumboo, J.2
Fong, K.Y.3
-
21
-
-
27744462578
-
Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus
-
Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005;14:856-8.
-
(2005)
Lupus
, vol.14
, pp. 856-858
-
-
Mak, A.1
Mok, C.C.2
-
22
-
-
0036785351
-
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
-
Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
-
(2002)
Ann Rheum Dis
, vol.61
, pp. 883-888
-
-
Leandro, M.J.1
Edwards, J.C.2
Cambridge, G.3
-
23
-
-
0032769336
-
The central and multiple roles of B cells in lupus pathogenesis
-
Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999;169:107-21.
-
(1999)
Immunol Rev
, vol.169
, pp. 107-121
-
-
Chan, O.T.1
Madaio, M.P.2
Shlomchik, M.J.3
-
24
-
-
33847068351
-
Drug insight: The mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis
-
Taylor RP, Lindorfer MA. Drug insight: The mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
-
(2007)
Nat Clin Pract Rheumatol
, vol.3
, pp. 86-95
-
-
Taylor, R.P.1
Lindorfer, M.A.2
-
25
-
-
0036877336
-
Mechanism of action of rituximab
-
Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs 2002;13(Suppl. 2):3-10.
-
(2002)
Anticancer Drugs
, vol.13
, Issue.SUPPL. 2
, pp. 3-10
-
-
Cerny, T.1
Borisch, B.2
Introna, M.3
Johnson, P.4
Rose, A.L.5
-
26
-
-
0036177919
-
Rituximab: Mechanism of action and resistance
-
Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 2002;29(1 Suppl. 2):2-9.
-
(2002)
Semin Oncol
, vol.29
, Issue.1 SUPPL. 2
, pp. 2-9
-
-
Maloney, D.G.1
Smith, B.2
Rose, A.3
-
27
-
-
28544449032
-
B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients
-
Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
-
(2005)
Rheumatology
, vol.44
, pp. 1542-1545
-
-
Leandro, M.J.1
Cambridge, G.2
Edwards, J.C.3
Ehrenstein, M.R.4
Isenberg, D.A.5
-
28
-
-
4043179907
-
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
-
Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 2580-2589
-
-
Looney, R.J.1
Anolik, J.H.2
Campbell, D.3
-
29
-
-
70350525210
-
Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study
-
Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006;8:R83.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Vigna-Perez, M.1
Hernandez-Castro, B.2
Paredes-Saharopulos, O.3
-
30
-
-
13444252282
-
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand
-
Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 2005;52:501-13.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 501-513
-
-
Sfikakis, P.P.1
Boletis, J.N.2
Lionaki, S.3
-
31
-
-
34247246405
-
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
-
Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 1263-1272
-
-
Gunnarsson, I.1
Sundelin, B.2
Jónsdóttir, T.3
Jacobson, S.H.4
Henriksson, E.W.5
van Vollenhoven, R.F.6
-
32
-
-
34147193717
-
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
-
Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 470-475
-
-
Tokunaga, M.1
Saito, K.2
Kawabata, D.3
-
33
-
-
39549108298
-
Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response
-
Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 330-334
-
-
Jónsdóttir, T.1
Gunnarsson, I.2
Risselada, A.3
Henriksson, E.W.4
Klareskog, L.5
van Vollenhoven, R.F.6
-
34
-
-
22144462880
-
Failure of rituximab to treat a lupus flare-up with nephritis
-
Lambotte O, Durbach A, Kotb R, Ferlicot S, Delfraissy JF, Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 2005;64:73-7.
-
(2005)
Clin Nephrol
, vol.64
, pp. 73-77
-
-
Lambotte, O.1
Durbach, A.2
Kotb, R.3
Ferlicot, S.4
Delfraissy, J.F.5
Goujard, C.6
-
35
-
-
63249122739
-
Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis (abstract)
-
Sangle SR, Davies RJ, Aslam L et al. Rituximab in the treatment of resistant systemic lupus erythematosus: Failure of therapy in rapidly progressive crescentic lupus nephritis (abstract). Rheumatology 2007;56:S215.
-
(2007)
Rheumatology
, vol.56
-
-
Sangle, S.R.1
Davies, R.J.2
Aslam, L.3
-
36
-
-
63249129834
-
-
Genentech and Biogen Idec. http://www.gene.com/gene/news/press-releases/ dis play.do?method=detail&id=11247 (19 December 2008, date last accessed).
-
Genentech and Biogen Idec. http://www.gene.com/gene/news/press-releases/ dis play.do?method=detail&id=11247 (19 December 2008, date last accessed).
-
-
-
-
37
-
-
34548151122
-
B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response
-
Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1259-1262
-
-
Ng, K.P.1
Cambridge, G.2
Leandro, M.J.3
Edwards, J.C.4
Ehrenstein, M.5
Isenberg, D.A.6
-
38
-
-
33745714540
-
Repeated B-cell depletion in treatment of refractory systemic lupus erythematosus
-
Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B-cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 942-945
-
-
Ng, K.P.1
Leandro, M.J.2
Edwards, J.C.3
Ehrenstein, M.R.4
Cambridge, G.5
Isenberg, D.A.6
-
39
-
-
33845869839
-
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
-
Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007;122:62-74.
-
(2007)
Clin Immunol
, vol.122
, pp. 62-74
-
-
Vallerskog, T.1
Gunnarsson, I.2
Widhe, M.3
-
40
-
-
8444223507
-
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
-
Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50:3580-90.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3580-3590
-
-
Anolik, J.H.1
Barnard, J.2
Cappione, A.3
-
41
-
-
0037289807
-
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
-
Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 455-459
-
-
Anolik, J.H.1
Campbell, D.2
Felgar, R.E.3
-
42
-
-
0041571732
-
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
-
Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146-54.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 2146-2154
-
-
Cambridge, G.1
Leandro, M.J.2
Edwards, J.C.3
-
43
-
-
33750964016
-
B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles
-
Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006;54:3612-22.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 3612-3622
-
-
Cambridge, G.1
Leandro, M.J.2
Teodorescu, M.3
-
44
-
-
34547488545
-
Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease
-
Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007;56:2116-28.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 2116-2128
-
-
Calabrese, L.H.1
Molloy, E.S.2
Huang, D.3
Ransohoff, R.M.4
-
45
-
-
63249084945
-
-
Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00626197?term=ocrelizumab&cond=lupus&rank=1 (19 December 2008, date last accessed).
-
Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00626197?term=ocrelizumab&cond=lupus&rank=1 (19 December 2008, date last accessed).
-
-
-
-
46
-
-
63249093130
-
-
Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00539838?term=ocrelizumab&cond=lupus&rank=2 (19 December 2008, date last accessed).
-
Genentech; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00539838?term=ocrelizumab&cond=lupus&rank=2 (19 December 2008, date last accessed).
-
-
-
-
47
-
-
53749095799
-
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
-
Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Dörner, T.1
Kaufmann, J.2
Wegener, W.A.3
Teoh, N.4
Goldenberg, D.M.5
Burmester, G.R.6
-
48
-
-
63249128038
-
-
UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00660881?term=epratuzumab&cond=lupus&rank=4 (19 December 2008, date last accessed).
-
UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00660881?term=epratuzumab&cond=lupus&rank=4 (19 December 2008, date last accessed).
-
-
-
-
49
-
-
63249133898
-
-
UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624351?term=epratuzumab&cond=lupus&rank=6 (19 December 2008, date last accessed).
-
UCB; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624351?term=epratuzumab&cond=lupus&rank=6 (19 December 2008, date last accessed).
-
-
-
-
50
-
-
10744224617
-
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations
-
Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 3475-3486
-
-
Stohl, W.1
Metyas, S.2
Tan, S.M.3
-
51
-
-
34548102544
-
Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial (abstract)
-
Furie R, Lisse J, Merrill JT et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial (abstract). Rheumatology 2006;54:S258.
-
(2006)
Rheumatology
, vol.54
-
-
Furie, R.1
Lisse, J.2
Merrill, J.T.3
-
52
-
-
34548542899
-
Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 Weeks (abstract)
-
Wallace DJ, Lisse J, Stohl W et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 Weeks (abstract). Rheumatology 2006;54:S790.
-
(2006)
Rheumatology
, vol.54
-
-
Wallace, D.J.1
Lisse, J.2
Stohl, W.3
-
53
-
-
63249120429
-
-
Human Genome Sciences. http://clinicaltrials.gov/ct2/show/NCT00410384 (19 December 2008, date last accessed).
-
Human Genome Sciences. http://clinicaltrials.gov/ct2/show/NCT00410384 (19 December 2008, date last accessed).
-
-
-
-
54
-
-
63249125886
-
Serum levels of TNF family members APRIL and BLyS are inversely correlated in SLE
-
Advance Access published August 2, doi: 10.1136/ard.2008.090928
-
Morel J, Roubille C, Planelles L et al. Serum levels of TNF family members APRIL and BLyS are inversely correlated in SLE. Ann Rheum Dis. Advance Access published August 2, 2008, doi: 10.1136/ard.2008.090928.
-
(2008)
Ann Rheum Dis
-
-
Morel, J.1
Roubille, C.2
Planelles, L.3
-
55
-
-
63249117211
-
-
EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624338?term=atacicept&rank=3 (19 December 2008, date last accessed).
-
EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00624338?term=atacicept&rank=3 (19 December 2008, date last accessed).
-
-
-
-
56
-
-
63249113118
-
-
EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show?term= atacicept&rank=6 (19 December 2008, date last accessed).
-
EMD Sereno; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show?term= atacicept&rank=6 (19 December 2008, date last accessed).
-
-
-
-
57
-
-
2942703965
-
LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus
-
Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004;13:323-27.
-
(2004)
Lupus
, vol.13
, pp. 323-327
-
-
Wallace, D.J.1
Tumlin, J.A.2
-
58
-
-
0037331980
-
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study
-
Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 442-454
-
-
Alarcon-Segovia, D.1
Tumlin, J.A.2
Furie, R.A.3
-
59
-
-
0141849087
-
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo
-
Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-86.
-
(2003)
Lupus
, vol.12
, pp. 677-686
-
-
Strand, V.1
Aranow, C.2
Cardiel, M.H.3
-
60
-
-
49449093009
-
LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial
-
Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2470-2480
-
-
Cardiel, M.H.1
Tumlin, J.A.2
Furie, R.A.3
Wallace, D.J.4
Joh, T.5
Linnik, M.D.6
-
61
-
-
63249107804
-
-
La Jolla Pharmaceutical Company; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00089804?term=LJP+394&rank=1 (19 December 2008, date last accessed).
-
La Jolla Pharmaceutical Company; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00089804?term=LJP+394&rank=1 (19 December 2008, date last accessed).
-
-
-
-
62
-
-
0033965079
-
Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
-
Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.
-
(2000)
Nat Med
, vol.6
, pp. 114
-
-
Kawai, T.1
Andrews, D.2
Colvin, R.B.3
Sachs, D.H.4
Cosimi, A.B.5
-
63
-
-
0038240916
-
Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE)
-
Davidson A, Wang X, Mihara M et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci 2003;987:188-98.
-
(2003)
Ann N Y Acad Sci
, vol.987
, pp. 188-198
-
-
Davidson, A.1
Wang, X.2
Mihara, M.3
-
64
-
-
0036272915
-
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus
-
Huang W, Sinha J, Newman J et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46:1554-62.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1554-1562
-
-
Huang, W.1
Sinha, J.2
Newman, J.3
-
65
-
-
0030267659
-
Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response
-
Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159-64.
-
(1996)
J Immunol
, vol.157
, pp. 3159-3164
-
-
Early, G.S.1
Zhao, W.2
Burns, C.M.3
-
66
-
-
0037333857
-
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
-
Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 719-727
-
-
Boumpas, D.T.1
Furie, R.2
Manzi, S.3
-
67
-
-
0036899589
-
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial
-
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46: 3251-8.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 3251-3258
-
-
Kalunian, K.C.1
Davis Jr, J.C.2
Merrill, J.T.3
Totoritis, M.C.4
Wofsy, D.5
-
68
-
-
0033932756
-
CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus
-
Mihara M, Tan I, Chuzhin Y et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
-
(2000)
J Clin Invest
, vol.106
, pp. 91-101
-
-
Mihara, M.1
Tan, I.2
Chuzhin, Y.3
-
69
-
-
0034605033
-
Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
-
Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
-
(2000)
J Exp Med
, vol.192
, pp. 681-694
-
-
Abrams, J.R.1
Kelley, S.L.2
Hayes, E.3
-
70
-
-
0033135564
-
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
-
Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103: 1243-52.
-
(1999)
J Clin Invest
, vol.103
, pp. 1243-1252
-
-
Abrams, J.R.1
Lebwohl, M.G.2
Guzzo, C.A.3
-
71
-
-
0036275436
-
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
-
Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-9.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1470-1479
-
-
Moreland, L.W.1
Alten, R.2
Van den Bosch, F.3
-
72
-
-
0242574700
-
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
-
Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
-
(2003)
N Engl J Med
, vol.349
, pp. 1907-1915
-
-
Kremer, J.M.1
Westhovens, R.2
Leon, M.3
-
73
-
-
0037868032
-
Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition
-
Schiffer L, Sinha J, Wang X et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003;171:489-97.
-
(2003)
J Immunol
, vol.171
, pp. 489-497
-
-
Schiffer, L.1
Sinha, J.2
Wang, X.3
-
74
-
-
0035284737
-
Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide
-
Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6.
-
(2001)
J Immunol
, vol.166
, pp. 2913-2916
-
-
Daikh, D.I.1
Wofsy, D.2
-
75
-
-
63249088064
-
-
Bristol-Myers Squibb; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/ show/NCT00430677 (19 December 2008, date last accessed).
-
Bristol-Myers Squibb; ClinicalTrials.gov. http://clinicaltrials.gov/ct2/ show/NCT00430677 (19 December 2008, date last accessed).
-
-
-
-
76
-
-
21744446004
-
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey
-
De Bandt M, Sibilia J, Le Loë X et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. Arthritis Res Ther 2005;7:R545-51.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
De Bandt, M.1
Sibilia, J.2
Le Loë, X.3
-
77
-
-
34447505845
-
Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases
-
Ramos-Casals M, Brito-Zerón P, Muñoz S et al. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine 2007;86:242-51.
-
(2007)
Medicine
, vol.86
, pp. 242-251
-
-
Ramos-Casals, M.1
Brito-Zerón, P.2
Muñoz, S.3
-
78
-
-
0043175226
-
SLE - complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus
-
Aringer M, Smolen JS. SLE - complex cytokine effects in a complex autoimmune disease: Tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003;5:172-7.
-
(2003)
Arthritis Res Ther
, vol.5
, pp. 172-177
-
-
Aringer, M.1
Smolen, J.S.2
-
79
-
-
5644258326
-
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study
-
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 2004;50:3161-9.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3161-3169
-
-
Aringer, M.1
Graninger, W.B.2
Steiner, G.3
Smolen, J.S.4
-
80
-
-
33846231376
-
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
-
Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007;56:274-9.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 274-279
-
-
Aringer, M.1
Steiner, G.2
Graninger, W.B.3
Höfler, E.4
Steiner, C.W.5
Smolen, J.S.6
-
81
-
-
33646696885
-
-
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85. Erratum in: J Am Med Assoc 2006;295:2482.
-
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85. Erratum in: J Am Med Assoc 2006;295:2482.
-
-
-
-
82
-
-
67549117204
-
The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure adjusted pooled analyses of serious adverse events
-
Advance Access published August 27, doi:10.1136/ard.2008.091025
-
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: Meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis. Advance Access published August 27, 2008, doi:10.1136/ard.2008.091025.
-
(2008)
Ann Rheum Dis
-
-
Leombruno, J.P.1
Einarson, T.R.2
Keystone, E.C.3
-
83
-
-
33747008410
-
-
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ. Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
-
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ. Symmons DP; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
-
-
-
-
84
-
-
0029764359
-
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
-
Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8563-8568
-
-
Wang, Y.1
Hu, Q.2
Madri, J.A.3
Rollins, S.A.4
Chodera, A.5
Matis, L.A.6
-
85
-
-
2942716917
-
Inhibition of terminal complement: A novel therapeutic approach for the treatment of systemic lupus erythematosus
-
Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004;13:328-34.
-
(2004)
Lupus
, vol.13
, pp. 328-334
-
-
Rother, R.P.1
Mojcik, C.F.2
McCroskery, E.W.3
-
86
-
-
0036113782
-
The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases
-
Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-74.
-
(2002)
Rheumatology
, vol.41
, pp. 367-374
-
-
Pyne, D.1
Ehrenstein, M.2
Morris, V.3
-
87
-
-
0033554258
-
Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
-
Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354:569-70.
-
(1999)
Lancet
, vol.354
, pp. 569-570
-
-
Boletis, J.N.1
Ioannidis, J.P.2
Boki, K.A.3
Moutsopoulos, H.M.4
-
88
-
-
0034098474
-
Intravenous immunoglobulin treatment of lupus nephritis
-
Levy Y, Sherer Y, George J et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 2000;29:321-7.
-
(2000)
Semin Arthritis Rheum
, vol.29
, pp. 321-327
-
-
Levy, Y.1
Sherer, Y.2
George, J.3
-
89
-
-
10444255401
-
Intravenous immunoglobulin and the kidney-a two-edged sword
-
Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 2004;34:593-601.
-
(2004)
Semin Arthritis Rheum
, vol.34
, pp. 593-601
-
-
Orbach, H.1
Tishler, M.2
Shoenfeld, Y.3
-
90
-
-
0042667057
-
Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin
-
Brennan VM, Salomé-Bentley NJ, Chapel HM. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133:247-51.
-
(2003)
Clin Exp Immunol
, vol.133
, pp. 247-251
-
-
Brennan, V.M.1
Salomé-Bentley, N.J.2
Chapel, H.M.3
-
92
-
-
12144286975
-
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR
-
Snowden JA, Passweg J, Moore JJ et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR. J Rheumatol 2004;31:482-8.
-
(2004)
J Rheumatol
, vol.31
, pp. 482-488
-
-
Snowden, J.A.1
Passweg, J.2
Moore, J.J.3
-
93
-
-
10744219522
-
High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus
-
Lisukov IA, Sizikova SA, Kulagin AD et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 2004;13:89-94.
-
(2004)
Lupus
, vol.13
, pp. 89-94
-
-
Lisukov, I.A.1
Sizikova, S.A.2
Kulagin, A.D.3
-
94
-
-
0036847280
-
Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients
-
Traynor AE, Barr WG, Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917-23.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2917-2923
-
-
Traynor, A.E.1
Barr, W.G.2
Rosa, R.M.3
-
95
-
-
0037235945
-
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus
-
Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48:166-73.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 166-173
-
-
Petri, M.1
Jones, R.J.2
Brodsky, R.A.3
-
96
-
-
32044473487
-
Non myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus
-
Burt RK, Traynor A, Statkute L et al. Non myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. J Am Med Assoc 2006;295: 527-35.
-
(2006)
J Am Med Assoc
, vol.295
, pp. 527-535
-
-
Burt, R.K.1
Traynor, A.2
Statkute, L.3
|